SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0000950170-23-061509
Filing Date
2023-11-09
Accepted
2023-11-09 07:03:00
Documents
14
Period of Report
2023-11-09
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K omga-20231109.htm   iXBRL 8-K 49756
2 EX-99.1 omga-ex99_1.htm EX-99.1 208081
3 GRAPHIC img220583725_0.jpg GRAPHIC 16872
  Complete submission text file 0000950170-23-061509.txt   417374

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT omga-20231109.xsd EX-101.SCH 2489
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT omga-20231109_pre.xml EX-101.PRE 11450
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT omga-20231109_lab.xml EX-101.LAB 13904
8 EXTRACTED XBRL INSTANCE DOCUMENT omga-20231109_htm.xml XML 4885
Mailing Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40657 | Film No.: 231389995
SIC: 2836 Biological Products, (No Diagnostic Substances)